Cost-effectiveness of statins revisited: Lessons learned about the value of innovation

European Journal of Health Economics

Volumn 13, Issue 4, 2012, Pages 445-450

  Lindgren, Peter ^a   Jönsson, Bengt ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Cardiovascular disease; Consumer surplus; Producer surplus; Simvastatin

Indexed keywords

SIMVASTATIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HUMAN; MEDICAL SOCIETY; MORBIDITY; PATENT; PRIORITY JOURNAL; REIMBURSEMENT; SWEDEN;

CARDIOVASCULAR DISEASES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG PRESCRIPTIONS; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SIMVASTATIN; SWEDEN;

EID: 84865578199     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-011-0315-1     Document Type: Article

References (38)

1. Weinstein, M.C., Coxson, P.G., Williams, L.W., Pass, T.M., Stason, W.B., Goldman, L.: Forecasting coronary heart disease incidence, mortality, and cost: The Coronary Heart Disease Policy Model. Am. J. Public Health 77(11), 1417-1426 (1987) (Pubitemid 18011588)
2. Goldman, L., Weinstein, M.C., Goldman, P.A., Williams, L.W.: Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 265(9), 1145-1151 (1991)
3. Tsevat, J., Weinstein, M.C., Williams, L.W., Tosteson, A.N., Goldman, L.: Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 83(4), 1194-1201 (1991)
4. Martens, L.L., Rutten, F.F., Erkelens, D.W., Ascoop, C.A.: Cost effectiveness of cholesterol-lowering therapy in The Netherlands Simvastatin versus cholestyramine. Am. J. Med. 87(4A), 54S-58S (1989)
5. Hjalte, K., Lindgren, B., Persson, U.: Cost-effectiveness of simvastatin versus cholestyramine: Results for Sweden. Pharmacoeconomics 1(3), 213-216 (1992)
6. Johannesson, M., Borgquist, L., Jonsson, B., Lindholm, L.H.: The cost effectiveness of lipid lowering in Swedish primary health care. The cell study group. J. Intern. Med. 240(1), 23-29 (1996) (Pubitemid 26255145)
7. Johannesson, M., Jonsson, B., Kjekshus, J., Olsson, A.G., Pedersen, T.R., Wedel, H.: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian simvastatin survival study group. N. Engl. J. Med. 336(5), 332-336 (1997) (Pubitemid 27057183)
8. Jonsson, B., Johannesson, M., Kjekshus, J., Olsson, A.G., Pedersen, T.R., Wedel, H.: Cost-effectiveness of cholesterol lowering. Results from the Scandinavian simvastatin survival study (4S). Eur. Heart J. 17(7), 1001-1007 (1996) (Pubitemid 26252516)
9. Glasziou, P.P., Eckermann, S.D., Mulray, S.E., Simes, R.J., Martin, A.J., Kirby, A.C., et al.: Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: Is it cost-effective? Med. J. Aust. 177(8), 428-434 (2002) (Pubitemid 35402001)
10. Gotto Jr, A.M., Boccuzzi, S.J., Cook, J.R., Alexander, C.M., Roehm, J.B., Meyer, G.S., et al.: Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS). AFCAPS/TexCAPS Research Group. Am. J. Cardiol. 86(11), 1176-1181 (2000)
11. Jonsson, B., Cook, J.R., Pedersen, T.R.: The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial. Diabetologia 42(11), 1293-1301 (1999) (Pubitemid 29500965)
12. Lindgren, P., Buxton, M., Kahan, T., Poulter, N.R., Dahlof, B., Sever, P.S., et al.: Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: An economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil 12(1), 29-36 (2005) (Pubitemid 40388290)
13. Mihaylova, B., Briggs, A., Armitage, J., Parish, S., Gray, A., Collins, R.: Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20, 536 individuals. Lancet 365(9473), 1779-1785 (2005)
14. Caro, J., Klittich, W., McGuire, A., Ford, I., Norrie, J., Pettitt, D., et al.: The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin. BMJ 315(7122), 1577-1582 (1997) (Pubitemid 27522398)
15. Lindgren, P., Graff, J., Olsson, A.G., Pedersen, T.J., Jonsson, B.: Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur. Heart J. 28(12), 1448-1453 (2007) (Pubitemid 47343816)
16. Mihaylova, B., Briggs, A., Armitage, J., Parish, S., Gray, A., Collins, R.: Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20, 536 people. BMJ 333(7579), 1145 (2006)
17. Cook, J.R., Yin, D., Alemao, E., Davies, G., Krobot, K.J., Veltri, E., et al.: Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: Application to Germany, Spain and Norway. Pharmacoeconomics 22(Suppl 3), 49-61 (2004) (Pubitemid 39481912)
18. Ara, R., Pandor, A., Tumur, I., Paisley, S., Duenas, A., Williams, R., et al.: Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registries. Clin Ther 30(8), 1508-1523 (2008)
19. Cook, J.R., Yin, D., Alemao, E., Drummond, M.: Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics 22(Suppl 3), 37-48 (2004) (Pubitemid 39481911)
20. Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., et al.: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005)
21. National board of Health and Welfare (2009) Official statistics of Sweden. Pharmaceuticals -statistics for 2008)
22. Lindgren, P., Jonsson, B.: From 4S to IDEAL: The health economics of the statin trials. Eur J Cardiovasc Prev Rehabil 16(2), 138-143 (2009)
23. Johannesson, M.: At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur. Heart J. 22(11), 919-925 (2001) (Pubitemid 32625214)
24. Jonsson, B.: Economics of drug treatment: For which patients is it costeffective to lower cholesterol? Lancet 358(9289), 1251-1256 (2001) (Pubitemid 33010854)
25. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360(9326), 7-22 (2002)
26. Ghatnekar, O., Persson, U., Glader, E.L., Terent, A.: Cost of stroke in Sweden: An incidence estimate. Int J Technol Assess Health Care 20(3), 375-380 (2004) (Pubitemid 39079575)
27. Meltzer, D.: Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16(1), 33-64 (1997) (Pubitemid 27224093)
28. Carlsson, A., Borgstrom, F., Stalhammar, J., Alemao, E., Yin, D., Jonsson, L.: Cost of care for patients treated with lipid-lowering drugs. Pharmacoeconomics 22(Suppl 3), 25-35 (2004) (Pubitemid 39481910)
29. Ekman, M.: Studies in health economics: Modelling and data analysis of costs and survival. Economic Research Institute, Stockholm School of Economics, Stockholm (2002)
30. SIKA: Samhällsekonomiska principer och kalkylvärden för transportsektorn: ASEK 4. SIKA. Report No: 2008: 3. (2008)
31. Hugosson, K., Engström, A.: Threshold value for a QALY -correlation with disease severity and decision uncertainty. Poster presented at ISPOR 13th annual international meeting, Toronto, 2008)
32. Lindgren, P., Kahan, T., Poulter, N., Buxton, M., Svarvar, P., Dahlof, B., et al.: Utility loss and indirect costs following cardiovascular events in hypertensive patients: The ASCOT health economic substudy. Eur J Health Econ 8(1), 25-30 (2007) (Pubitemid 46295335)
33. Lindgren, P., Glader, E.L., Jonsson, B.: Utility loss and indirect costs after stroke in Sweden. Eur J Cardiovasc Prev Rehabil 15(2), 230-233 (2008) (Pubitemid 351507658)
34. Burstrom, K., Johannesson, M., Diderichsen, F.: Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 55(1), 51-69 (2001) (Pubitemid 32008478)
35. Jena, A.B., Philipson, T.J.: Innovation and technology adoption in health care markets. The American Enterprise Institute, Washington DC (2008)
36. Geweke, J., Weisbrod, B.A.: Some economic consequences of technological advance in medical care: The case of a new drug. Institute for Research on Poverty, University of Wisconsin-Madison. 1980 Apr. Report No.: DP# 602-680)
37. Bjorck, L., Rosengren, A., Bennett, K., Lappas, G., Capewell, S.: Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur. Heart J. 30(9), 1046-1056 (2009)
38. Ford, E.S., Ajani, U.A., Croft, J.B., Critchley, J.A., Labarthe, D.R., Kottke, T.E., et al.: Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N. Engl. J. Med. 356(23), 2388-2398 (2007) (Pubitemid 46883773)